Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.55 |
| ▸ | BTK | Q06187 | 5/20 | 0.52 |
| ▸ | JAK3 | P52333 | 3/20 | 0.52 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564058 | 1.00 | MAP4K4 (0.55) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL1710231 | 0.93 | MAP4K4 (0.57) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL1710581 | 0.93 | MAP4K4 (0.57) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL1710229 | 0.93 | MAP4K4 (0.57) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL27796432 | 0.91 | MAP4K4 (0.47) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL23497661 | 0.87 | BTK (0.49) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL13156590 | 0.86 | MAP4K4 (0.49) | MAP4K4BTKJAK3PDE10ASYK | |
| SCHEMBL1710216 | 0.86 | MAP4K4 (0.49) | MAP4K4BTKJAK3PDE10ASYK | |
| SCHEMBL1710218 | 0.86 | MAP4K4 (0.49) | MAP4K4BTKJAK3PDE10ASYK | |
| SCHEMBL13156648 | 0.86 | MAP4K4 (0.56) | MAP4K4BTKJAK3AURKAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | PIM1, PIM2, PIM3 | MAP4K4 255/4885BTK 95/4885JAK3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.